DE69934108T2 - Kombinierte Impfstoffe gegen Hepatitis A und Hepatitis B - Google Patents
Kombinierte Impfstoffe gegen Hepatitis A und Hepatitis B Download PDFInfo
- Publication number
- DE69934108T2 DE69934108T2 DE69934108T DE69934108T DE69934108T2 DE 69934108 T2 DE69934108 T2 DE 69934108T2 DE 69934108 T DE69934108 T DE 69934108T DE 69934108 T DE69934108 T DE 69934108T DE 69934108 T2 DE69934108 T2 DE 69934108T2
- Authority
- DE
- Germany
- Prior art keywords
- hepatitis
- hbsag
- formol
- hav
- dose
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Lifetime
Links
- 229960005486 vaccine Drugs 0.000 title claims description 34
- 208000002672 hepatitis B Diseases 0.000 title claims description 26
- 208000005252 hepatitis A Diseases 0.000 title claims description 14
- WSFSSNUMVMOOMR-UHFFFAOYSA-N Formaldehyde Chemical compound O=C WSFSSNUMVMOOMR-UHFFFAOYSA-N 0.000 claims description 29
- 229960004279 formaldehyde Drugs 0.000 claims description 25
- 235000019256 formaldehyde Nutrition 0.000 claims description 25
- 239000000203 mixture Substances 0.000 claims description 24
- 239000000427 antigen Substances 0.000 claims description 23
- 102000036639 antigens Human genes 0.000 claims description 23
- 108091007433 antigens Proteins 0.000 claims description 23
- ILRRQNADMUWWFW-UHFFFAOYSA-K aluminium phosphate Chemical compound O1[Al]2OP1(=O)O2 ILRRQNADMUWWFW-UHFFFAOYSA-K 0.000 claims description 14
- 241000709721 Hepatovirus A Species 0.000 claims description 12
- WNROFYMDJYEPJX-UHFFFAOYSA-K aluminium hydroxide Chemical compound [OH-].[OH-].[OH-].[Al+3] WNROFYMDJYEPJX-UHFFFAOYSA-K 0.000 claims description 11
- 101710137302 Surface antigen S Proteins 0.000 claims description 4
- AZDRQVAHHNSJOQ-UHFFFAOYSA-N alumane Chemical class [AlH3] AZDRQVAHHNSJOQ-UHFFFAOYSA-N 0.000 claims description 4
- 230000002480 immunoprotective effect Effects 0.000 claims description 3
- 238000002360 preparation method Methods 0.000 claims description 2
- WSFSSNUMVMOOMR-NJFSPNSNSA-N methanone Chemical compound O=[14CH2] WSFSSNUMVMOOMR-NJFSPNSNSA-N 0.000 claims 1
- 238000009472 formulation Methods 0.000 description 8
- 150000003839 salts Chemical class 0.000 description 8
- 229940024545 aluminum hydroxide Drugs 0.000 description 6
- 229940124922 Twinrix Drugs 0.000 description 5
- 102000004169 proteins and genes Human genes 0.000 description 5
- 108090000623 proteins and genes Proteins 0.000 description 5
- 125000003275 alpha amino acid group Chemical group 0.000 description 4
- 229960000074 biopharmaceutical Drugs 0.000 description 4
- 239000000546 pharmaceutical excipient Substances 0.000 description 4
- 101000874347 Streptococcus agalactiae IgA FC receptor Proteins 0.000 description 3
- 238000004519 manufacturing process Methods 0.000 description 3
- 102100031673 Corneodesmosin Human genes 0.000 description 2
- 229940124884 Engerix-B Drugs 0.000 description 2
- 101001065501 Escherichia phage MS2 Lysis protein Proteins 0.000 description 2
- 229940124914 Havrix Drugs 0.000 description 2
- 229940096437 Protein S Drugs 0.000 description 2
- 108010031318 Vitronectin Proteins 0.000 description 2
- 239000013065 commercial product Substances 0.000 description 2
- 229940035032 monophosphoryl lipid a Drugs 0.000 description 2
- 230000002265 prevention Effects 0.000 description 2
- 241000700721 Hepatitis B virus Species 0.000 description 1
- XAGFODPZIPBFFR-UHFFFAOYSA-N aluminium Chemical compound [Al] XAGFODPZIPBFFR-UHFFFAOYSA-N 0.000 description 1
- 229910052782 aluminium Inorganic materials 0.000 description 1
- 229940024546 aluminum hydroxide gel Drugs 0.000 description 1
- SMYKVLBUSSNXMV-UHFFFAOYSA-K aluminum;trihydroxide;hydrate Chemical compound O.[OH-].[OH-].[OH-].[Al+3] SMYKVLBUSSNXMV-UHFFFAOYSA-K 0.000 description 1
- 150000001413 amino acids Chemical class 0.000 description 1
- 230000002238 attenuated effect Effects 0.000 description 1
- 229940001442 combination vaccine Drugs 0.000 description 1
- 239000011246 composite particle Substances 0.000 description 1
- 230000021615 conjugation Effects 0.000 description 1
- 238000007796 conventional method Methods 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 230000018109 developmental process Effects 0.000 description 1
- 230000000694 effects Effects 0.000 description 1
- 238000005538 encapsulation Methods 0.000 description 1
- 239000012634 fragment Substances 0.000 description 1
- 208000006454 hepatitis Diseases 0.000 description 1
- 231100000283 hepatitis Toxicity 0.000 description 1
- 230000005965 immune activity Effects 0.000 description 1
- 230000028993 immune response Effects 0.000 description 1
- 230000003053 immunization Effects 0.000 description 1
- 238000002649 immunization Methods 0.000 description 1
- 239000002502 liposome Substances 0.000 description 1
- 229920002521 macromolecule Polymers 0.000 description 1
- 229920001184 polypeptide Polymers 0.000 description 1
- 102000004196 processed proteins & peptides Human genes 0.000 description 1
- 108090000765 processed proteins & peptides Proteins 0.000 description 1
- 238000011321 prophylaxis Methods 0.000 description 1
- 230000004224 protection Effects 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/12—Viral antigens
- A61K39/29—Hepatitis virus
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/12—Viral antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/12—Viral antigens
- A61K39/125—Picornaviridae, e.g. calicivirus
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/12—Viral antigens
- A61K39/29—Hepatitis virus
- A61K39/292—Serum hepatitis virus, hepatitis B virus, e.g. Australia antigen
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/20—Antivirals for DNA viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/04—Immunostimulants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
- A61K2039/525—Virus
- A61K2039/5252—Virus inactivated (killed)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/55—Medicinal preparations containing antigens or antibodies characterised by the host/recipient, e.g. newborn with maternal antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
- A61K2039/55505—Inorganic adjuvants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/70—Multivalent vaccine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2730/00—Reverse transcribing DNA viruses
- C12N2730/00011—Details
- C12N2730/10011—Hepadnaviridae
- C12N2730/10111—Orthohepadnavirus, e.g. hepatitis B virus
- C12N2730/10134—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
- C12N2770/00011—Details
- C12N2770/32011—Picornaviridae
- C12N2770/32411—Hepatovirus, i.e. hepatitis A virus
- C12N2770/32434—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Virology (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Chemical & Material Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Immunology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Communicable Diseases (AREA)
- Microbiology (AREA)
- Mycology (AREA)
- Epidemiology (AREA)
- Oncology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Molecular Biology (AREA)
- Gastroenterology & Hepatology (AREA)
- Biotechnology (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Medicinal Preparation (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GB9809507 | 1998-05-01 | ||
| GBGB9809507.8A GB9809507D0 (en) | 1998-05-01 | 1998-05-01 | Novel composition |
| PCT/EP1999/003024 WO1999056772A2 (en) | 1998-05-01 | 1999-04-27 | Hepatitis vaccine |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| DE69934108D1 DE69934108D1 (de) | 2007-01-04 |
| DE69934108T2 true DE69934108T2 (de) | 2007-04-19 |
Family
ID=10831426
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| DE69934108T Expired - Lifetime DE69934108T2 (de) | 1998-05-01 | 1999-04-27 | Kombinierte Impfstoffe gegen Hepatitis A und Hepatitis B |
Country Status (28)
| Country | Link |
|---|---|
| EP (1) | EP1073462B1 (enExample) |
| JP (2) | JP5138843B2 (enExample) |
| KR (1) | KR100612547B1 (enExample) |
| CN (1) | CN1263509C (enExample) |
| AR (1) | AR016987A1 (enExample) |
| AT (1) | ATE345815T1 (enExample) |
| AU (1) | AU743759B2 (enExample) |
| BR (1) | BR9910157A (enExample) |
| CA (1) | CA2331086C (enExample) |
| CO (1) | CO5050367A1 (enExample) |
| CY (1) | CY1107322T1 (enExample) |
| CZ (1) | CZ301232B6 (enExample) |
| DE (1) | DE69934108T2 (enExample) |
| DK (1) | DK1073462T3 (enExample) |
| ES (1) | ES2277437T3 (enExample) |
| GB (1) | GB9809507D0 (enExample) |
| GC (1) | GC0000101A (enExample) |
| HU (1) | HU228209B1 (enExample) |
| IL (1) | IL139269A0 (enExample) |
| MY (1) | MY128929A (enExample) |
| NO (1) | NO20005483L (enExample) |
| NZ (1) | NZ507902A (enExample) |
| PL (1) | PL190729B1 (enExample) |
| PT (1) | PT1073462E (enExample) |
| TR (1) | TR200003235T2 (enExample) |
| TW (1) | TW553744B (enExample) |
| WO (1) | WO1999056772A2 (enExample) |
| ZA (1) | ZA200006118B (enExample) |
Families Citing this family (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1513555A (zh) * | 2003-07-31 | 2004-07-21 | 长春生物制品研究所 | 甲-乙型肝炎联合疫苗及其冻干制剂 |
| EP1862176A1 (de) * | 2006-05-31 | 2007-12-05 | Rhein Biotech Gesellschaft für neue biotechnologische Prozesse und Produkte mbH | Ein Verfahren zur Herstellung einer Impfzusammensetzung |
| EP1862177A1 (de) * | 2006-06-01 | 2007-12-05 | Rhein Biotech Gesellschaft für neue biotechnologische Prozesse und Produkte mbH | Ein Verfahren zur Herstellung einer Impfzusammensetzung |
| CN102198270B (zh) * | 2011-05-16 | 2012-06-27 | 大连汉信生物制药有限公司 | 一种含铝佐剂乙肝疫苗的制备方法 |
| KR101281098B1 (ko) * | 2011-06-30 | 2013-07-02 | 주식회사 녹십자 | Ｂ형 간염 바이러스 표면 항원상의 에피토프 및 이의 용도 |
| CN102988975A (zh) * | 2012-11-30 | 2013-03-27 | 深圳康泰生物制品股份有限公司 | 甲型、乙型肝炎联合疫苗及其制备方法 |
| US9849066B2 (en) | 2013-04-24 | 2017-12-26 | Corning Incorporated | Delamination resistant pharmaceutical glass containers containing active pharmaceutical ingredients |
| WO2020099927A1 (en) * | 2018-11-13 | 2020-05-22 | Variation Biotechnologies Inc. | Immunogenic compositions for treatment of hepatitis b |
Family Cites Families (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPH0349686A (ja) * | 1989-07-11 | 1991-03-04 | Smithkline Biologicals Sa | レトロウイルスｇａｇ蛋白の真核生物細胞における発現 |
| RU2160120C2 (ru) * | 1992-05-23 | 2000-12-10 | Смитклайн Бичам Байолоджикалс С.А. | Комбинированная вакцина на основе поверхностного антигена вируса гепатита в, способ ее получения и способ предупреждения инфекции гепатита в у человека |
| GB9503863D0 (en) * | 1995-02-25 | 1995-04-19 | Smithkline Beecham Biolog | Vaccine compositions |
| US6372225B1 (en) * | 1996-03-23 | 2002-04-16 | The Research Foundation Of Microbial Diseases Of Osaka University | Tetanus toxin functional fragment antigen and tetanus vaccine |
-
1998
- 1998-05-01 GB GBGB9809507.8A patent/GB9809507D0/en not_active Ceased
-
1999
- 1999-04-27 CZ CZ20004061A patent/CZ301232B6/cs not_active IP Right Cessation
- 1999-04-27 DK DK99924871T patent/DK1073462T3/da active
- 1999-04-27 TR TR2000/03235T patent/TR200003235T2/xx unknown
- 1999-04-27 CA CA2331086A patent/CA2331086C/en not_active Expired - Lifetime
- 1999-04-27 ES ES99924871T patent/ES2277437T3/es not_active Expired - Lifetime
- 1999-04-27 EP EP99924871A patent/EP1073462B1/en not_active Expired - Lifetime
- 1999-04-27 GC GCP1999139 patent/GC0000101A/xx active
- 1999-04-27 KR KR1020007012162A patent/KR100612547B1/ko not_active Expired - Lifetime
- 1999-04-27 NZ NZ507902A patent/NZ507902A/en unknown
- 1999-04-27 AU AU41379/99A patent/AU743759B2/en not_active Expired
- 1999-04-27 DE DE69934108T patent/DE69934108T2/de not_active Expired - Lifetime
- 1999-04-27 IL IL13926999A patent/IL139269A0/xx not_active IP Right Cessation
- 1999-04-27 BR BR9910157-2A patent/BR9910157A/pt not_active Application Discontinuation
- 1999-04-27 CN CNB998081418A patent/CN1263509C/zh not_active Expired - Lifetime
- 1999-04-27 PT PT99924871T patent/PT1073462E/pt unknown
- 1999-04-27 HU HU0101652A patent/HU228209B1/hu unknown
- 1999-04-27 PL PL99344137A patent/PL190729B1/pl unknown
- 1999-04-27 JP JP2000546796A patent/JP5138843B2/ja not_active Expired - Lifetime
- 1999-04-27 AT AT99924871T patent/ATE345815T1/de active
- 1999-04-27 WO PCT/EP1999/003024 patent/WO1999056772A2/en not_active Ceased
- 1999-04-29 AR ARP990102002A patent/AR016987A1/es unknown
- 1999-04-29 CO CO99025940A patent/CO5050367A1/es unknown
- 1999-04-29 MY MYPI99001705A patent/MY128929A/en unknown
- 1999-06-29 TW TW088110991A patent/TW553744B/zh not_active IP Right Cessation
-
2000
- 2000-10-30 ZA ZA200006118A patent/ZA200006118B/xx unknown
- 2000-10-31 NO NO20005483A patent/NO20005483L/no not_active Application Discontinuation
-
2007
- 2007-02-08 CY CY20071100163T patent/CY1107322T1/el unknown
-
2010
- 2010-06-29 JP JP2010148061A patent/JP2010209118A/ja active Pending
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| DE69319728T2 (de) | Kombinierte Impfstoffe, die Hepatitis B oberfläche Antigen und andere Antigenen enthalten | |
| DE69617211T2 (de) | Hepatitis b impfstoff | |
| EP1090642B1 (en) | Vaccines comprising a polysaccharide antigen-carrier protein conjugate and free carrier protein | |
| DE69306940T2 (de) | 3-0-deacyliertes Monophosphoryl-Lipid-A enthaltende Hepatitis-Impfstoffe | |
| DE69715031T2 (de) | Azellulärer pertussis-impfstoff, der ein diphtherie-toxoid und ein tetanus-toxoid enthält | |
| DE69934108T2 (de) | Kombinierte Impfstoffe gegen Hepatitis A und Hepatitis B | |
| US7144703B2 (en) | Composition | |
| DE69729800T2 (de) | Bordetella pertussis aussermembran proteinfragmente enthaltende impfstoffzusammensetzung | |
| US8623380B2 (en) | Acellular pertussis vaccine with diphthriae- and tetanus-toxoids | |
| HK1034202B (en) | Combined vaccine against hepatitis a and hepatitis b | |
| HK1147950A (en) | Combined vaccines comprising hepatitis b surface antigen and other antigens | |
| HK1011290B (en) | Combined vaccines comprising hepatitis b surface antigen and other antigens | |
| HK1021142B (en) | Combined vaccines comprising hepatitis b surface antigen and other antigens | |
| HK1137937A (en) | Combined vaccines comprising hepatitis b surface antigen and other antigens |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| 8364 | No opposition during term of opposition |